Ending decades of prostate cancer overtreatment.
Garde is a non-invasive, urine-based diagnostic platform built on exosomal small non-coding RNA and supervised machine learning. We start with prostate cancer because the founding team has deep domain expertise in the field, and because the existing standard of care, the PSA test, is forty-five years old and demonstrably broken.
Why Garde. Why now.
Fix the broken funnel
The PSA test drives high false-positive rates, leading to costly biopsies and widespread overtreatment. Clinicians need actionable risk stratification. Garde delivers it from a urine sample in 24 hours.
Payor-relevant economics
Eliminating avoidable biopsies and overtreatment cuts direct costs for payors and spares patients the lifelong complications that follow. The economics align with the clinical incentives.
Wedge first, then platform
Prostate cancer is the wedge: high volume, clear clinical pathway, and deep founder-team expertise. The same urine-to-sncRNA workflow extends to endometrial, bladder, pancreatic, and renal indications.
A large, payor-relevant market with a clear unmet need.
Billions are spent each year on unnecessary biopsies and overtreatment driven by false-positive PSA results. The market is large, growing, and the dominant workflow is clearly broken.
The American Urological Association has called for biomarker testing to replace PSA-alone decisions. The regulatory pathway is established and reimbursement is well-understood.
This is not the team's first diagnostic.
The founding team previously built an award-winning company, shipped a CLIA-certified molecular test, and earned an FDA Breakthrough Device Designation. Their combined research record spans more than 300 peer-reviewed publications.
The new IP is independent. The architecture is tighter. They know what the first company got right and what to do differently.
Meet the full teamFrom validation study to commercial scale.
Company founded; new IP established
Garde formed by Rob Tenniswood with Drs. Martin Tenniswood, Winnie Wang, and Greg DiRienzo. Independent IP base built from the ground up.
Test design, R&D lab build-out, initial algorithm
Initial algorithm development complete. Validation cohort partnerships agreed. R&D laboratory operational.
600-patient validation study, health economics, FDA pre-sub prep
600-patient validation study with the Vancouver Prostate Centre prepared to launch. Health economics analysis in development. Roboticization of the lab workflow in development.
Clinical study, regulatory submissions (Canada), FDA pre-sub
Move into the formal clinical study. Regulatory submission in Canada. FDA pre-submission filed.
Publication, partnerships, regulatory submissions (EU)
Peer-reviewed publication of clinical results. Reference lab and contract sales organization partnerships. EU regulatory submission.
Commercial launch; FDA Breakthrough + 510(k) submission
Begin commercial sales in Canada and the EU. FDA Breakthrough Device Designation and 510(k) submission. Endometrial cancer R&D underway.
We're actively meeting with investors.
This round funds the validation study launch and the early clinical pathway in the U.S. and Canada. Round details, financial projections, and the full investor data room are available on request.
Ready for a deeper conversation?
We'll share the full deck, validation study design, and IP overview.